Intellia's CRISPR Comeback: How Gene Editing Pioneer Navigated Safety Concerns to Resume Pivotal Trials

Intellia Therapeutics announces FDA lift of clinical hold on MAGNITUDE-2 Phase 3 trial for its CRISPR-based therapy targeting hereditary transthyretin amyloidosis, marking a crucial milestone in navigating safety concerns in gene editing.

Scancell Secures FDA Clearance for Pivotal Phase 3 Melanoma Trial as Novel Immunotherapy Shows 24-Point Survival Advantage

UK-based Scancell Holdings announced FDA clearance for its Phase 3 trial of iSCIB1+, a novel DNA immunotherapy for advanced melanoma, following compelling Phase 2 data showing a 24-percentage-point improvement in progression-free survival.

This Tiny Biotech Stock Could Unlock a New Approach to Pancreatic Cancer Treatment (NASDAQ: SLXN)

COVID-19 vaccines did more than help end a global pandemic. They also introduced the public to a once-fringe idea: RNA itself can be medicine. Silexion Therapeutics is using RNAi to advance a next generation potential therapy for once of the toughest cancers | NASDAQ: SLXN

FDA Accepts First-Ever Quality Control Standard for Mesenchymal Stromal Cells, Setting New Benchmark for Cell Therapy Industry

The FDA's acceptance of Tasly's 3P Characterization of MSCs Assay marks the first FDA-recognized quality control standard for mesenchymal stromal cells, establishing a new benchmark for the cell therapy industry and accelerating the path to consistent, safe, and effective MSC-based therapies.

Wugen Achieves Historic Milestone: First Allogeneic CAR-T Therapy Earns FDA Breakthrough Status for T-Cell Leukemia

Wugen's soficabtagene geleucel receives FDA Breakthrough Therapy Designation as the first allogeneic CAR-T therapy for T-cell leukemia, marking a transformative milestone in cell therapy innovation.

Nasus Pharma's Positive Phase 2 Interim Data Signals Significant Advancements in Anaphylaxis Treatment

Nasus Pharma (NYSE: NSRX) announced compelling interim Phase 2 results this week for NS002, its investigational intranasal epinephrine powder, demonstrating pharmacokinetic advantages over the standard-of-care EpiPen autoinjector. The data showed NS002 achieved both faster absorption and higher peak concentrations of epinephrine—critical factors in a medical emergency where every minute

Hyundai Bioscience Pioneers Universal Antiviral Approach as XAFTY Advances to Phase 2 Trials Targeting Multiple Viral Threats

Hyundai Bioscience announces Phase 2 FDA trials for XAFTY, a revolutionary broad-spectrum antiviral targeting multiple viral threats including dengue, influenza, COVID-19, and RSV.

Eli Lilly's Ovarian Cancer Breakthrough: FDA Grants Rare Designation to Novel ADC Targeting Treatment-Resistant Disease

Eli Lilly announced FDA Breakthrough Therapy Designation for sofetabart mipitecan (LY4170156), a novel folate receptor alpha-targeted ADC for platinum-resistant ovarian cancer, offering hope to patients with limited treatment options.

D3 Bio Advances KRAS-Targeted Cancer Pipeline as FDA Clears Two Critical Clinical Programs

In a significant regulatory milestone that underscores the growing momentum in precision oncology, Shanghai-based D3 Bio announced today that the U.S. Food and Drug Administration has cleared two Investigational New Drug (IND) applications, enabling the company to advance its next-generation KRAS-targeted therapies into critical clinical trials. The dual clearance

Antengene's Next-Generation Cancer Arsenal Shows Promise as ADC Platform Delivers Strong Clinical Results

Antengene Corporation presented compelling clinical data at the J.P. Morgan Healthcare Conference, showcasing robust efficacy results for its lead antibody-drug conjugate (ADC) and unveiling an ambitious pipeline of next-generation cancer treatments.

Novartis Achieves Historic Milestone: Ianalumab Becomes First Targeted Therapy to Earn FDA Breakthrough Status for Sjögren's Disease

Novartis announces FDA Breakthrough Therapy Designation for ianalumab in Sjögren's disease, marking the first targeted therapy to receive this recognition for the autoimmune condition.

Ipsen's Revolutionary Cancer Immunotherapy Earns FDA Breakthrough Status in Blood Cancer Fight

In a significant advancement for cancer immunotherapy, French pharmaceutical company Ipsen announced on January 13, 2026, that the FDA has granted Breakthrough Therapy Designation to IPN60340 (ICT01), a first-in-class monoclonal antibody targeting acute myeloid leukemia (AML). This regulatory milestone positions the therapy as a potentially transformative treatment for one of